Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
A murine model of hnRNPH2-related neurodevelopmental disorder reveals a mechanism for genetic compensation by Hnrnph1
Ane Korff, … , J. Paul Taylor, Hong Joo Kim
Ane Korff, … , J. Paul Taylor, Hong Joo Kim
Published July 17, 2023
Citation Information: J Clin Invest. 2023;133(14):e160309. https://doi.org/10.1172/JCI160309.
View: Text | PDF | Erratum
Research Article Neuroscience Article has an altmetric score of 3

A murine model of hnRNPH2-related neurodevelopmental disorder reveals a mechanism for genetic compensation by Hnrnph1

  • Text
  • PDF
Abstract

Mutations in HNRNPH2 cause an X-linked neurodevelopmental disorder with features that include developmental delay, motor function deficits, and seizures. More than 90% of patients with hnRNPH2 have a missense mutation within or adjacent to the nuclear localization signal (NLS) of hnRNPH2. Here, we report that hnRNPH2 NLS mutations caused reduced interaction with the nuclear transport receptor Kapβ2 and resulted in modest cytoplasmic accumulation of hnRNPH2. We generated 2 knockin mouse models with human-equivalent mutations in Hnrnph2 as well as Hnrnph2-KO mice. Knockin mice recapitulated clinical features of the human disorder, including reduced survival in male mice, impaired motor and cognitive functions, and increased susceptibility to audiogenic seizures. In contrast, 2 independent lines of Hnrnph2-KO mice showed no detectable phenotypes. Notably, KO mice had upregulated expression of Hnrnph1, a paralog of Hnrnph2, whereas knockin mice failed to upregulate Hnrnph1. Thus, genetic compensation by Hnrnph1 may counteract the loss of hnRNPH2. These findings suggest that HNRNPH2-related disorder may be driven by a toxic gain of function or a complex loss of HNRNPH2 function with impaired compensation by HNRNPH1. The knockin mice described here are an important resource for preclinical studies to assess the therapeutic benefit of gene replacement or knockdown of mutant hnRNPH2.

Authors

Ane Korff, Xiaojing Yang, Kevin O’Donovan, Abner Gonzalez, Brett J.W. Teubner, Haruko Nakamura, James Messing, Fen Yang, Alexandre F. Carisey, Yong-Dong Wang, Tushar Patni, Heather Sheppard, Stanislav S. Zakharenko, Yuh Min Chook, J. Paul Taylor, Hong Joo Kim

×

Figure 1

Pathogenic variants alter the nucleocytoplasmic ratio of hnRNPH2 and enhance its recruitment to RNP granules.

Options: View larger image (or click on image) Download as PowerPoint
Pathogenic variants alter the nucleocytoplasmic ratio of hnRNPH2 and enh...
(A) Schematic of hnRNPH2, with red circles indicating mutations in patients with neurodevelopmental disorder. RRM1, RRM2, and RRM3, RNA recognition motifs 1, 2, and 3; PY-NLS, proline-tyrosine nuclear localization signal; LCD, low complexity domain. (B) Sequences of human paralogs of the hnRNP F/H family. Yellow indicates consensus PY-NLS motifs; red font indicates patient mutations. (C) Intracellular localization of FLAG-hnRNPH2 (WT and indicated mutants) under basal (left) and stressed (right) conditions in HeLa cells. hnRNPH antibody shows localization of endogenous hnRNPH1 and hnRNPH2. eIF3η was used as a cytoplasmic and stress granule marker. The regions within the white boxes are shown at higher magnification in the “Inset” column. Scale bar: 10 μm. (D) Quantification of hnRNPH2 cytoplasmic signal intensity as shown in C. An interleaved scatterplot with individual data points is shown; data are shown as the mean ± SD. For WT, R206W, R206Q, and P209L mutants, n = 24, 19, 21, and 18 cells for basal conditions and n = 24, 19, 22, and 15 cells for stressed conditions, respectively. ****P < 0.0001 by 1-way ANOVA with Dunnett’s post test. (E) Immunoblot (representative of n ≥ 3 experiments) showing comparable levels of expression between hnRNPH2 WT and indicated mutants. Quantified relative expression levels are indicated. (F) Summary of intracellular localization of FLAG-hnRNPH2 WT and mutants in HeLa cells, with or without arsenite stress. Images are shown in Supplemental Figure 1. Proteins with PY-NLS mutations (red font) showed cytoplasmic accumulation.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 6 X users
14 readers on Mendeley
See more details